Cervical Screening 2026: You Can Now Collect Your Own Sample

For many people, the speculum exam is the single biggest reason a cervical screening gets put off year after year. In 2026, that barrier got a little smaller.

In April 2026, the American College of Obstetricians and Gynecologists (ACOG) updated its cervical cancer screening guidance to include, for the first time, an option to collect your own sample for high-risk HPV testing. The change brings major US guidance in line with a parallel American Cancer Society update and with programs already running in the UK.

This article explains what HPV screening actually checks for, exactly what changed in 2026, how self-collection works, who it is and is not for, and how to bring it up with your clinician.

What HPV and cervical screening actually are

Almost all cervical cancer is caused by persistent infection with high-risk types of human papillomavirus (HPV), a very common virus passed through skin-to-skin and sexual contact. Most HPV infections clear on their own within a year or two. A small number persist and, over many years, can cause precancerous changes in the cervix that may eventually become cancer.

Cervical screening is designed to catch those changes before they ever become cancer. There are three established methods:

• Cytology (the Pap test), which looks at cervical cells under a microscope for abnormal changes.
• Primary high-risk HPV (hrHPV) testing, which looks directly for the high-risk virus types that cause nearly all cervical cancer.
• Co-testing, which runs an HPV test and a Pap test together.

Traditionally, all three require a clinician to insert a speculum and use a small brush to collect cells from the cervix. That step is what self-collection changes.

What changed in 2026

On April 24, 2026, ACOG published updated cervical cancer screening guidance, Committee Statement Number 28, in the journal Obstetrics & Gynecology. It replaces ACOG's previous Practice Advisory from April 2021.

The statement offers what ACOG calls a qualified endorsement of the 2026 Women's Preventive Services Initiative (WPSI) guidelines. "Qualified" matters: ACOG supports self-collection as an option but attaches conditions about how it should be offered, which we cover below.

The guidance addresses average-risk patients in three age groups. Here is the short version of the recommended intervals:

• Ages 21 to 29: cytology (Pap test) every 3 years.
• Ages 30 to 65: primary clinician-collected hrHPV testing every 5 years is the preferred approach. Co-testing every 5 years is an alternative, and cytology alone every 3 years is reserved for when primary HPV testing is not available.
• Ages 30 to 65, new option: self-collected hrHPV testing every 3 years, using an FDA-approved kit.
• Older than 65: screening can generally stop if you have an adequate history of normal results, but should continue if you were inadequately screened earlier or remain at higher risk.

The headline is that self-collected hrHPV testing is now an accepted screening option for average-risk people aged 30 to 65. Note the interval difference: clinician-collected primary HPV is recommended every five years, while the self-collected route is recommended every three years.

This did not happen in isolation. The American Cancer Society published its own 2026 update (Perkins and colleagues, in CA: A Cancer Journal for Clinicians) expanding its guideline to include self-collected vaginal specimens as an acceptable form of primary HPV testing, plus refreshed guidance on when to exit screening. The two updates point in the same direction.

What self-collection is and how it works

Self-collection means you take the sample yourself, rather than a clinician collecting it during a speculum exam.

In practice, you use a swab, similar to a long cotton bud, to gently take a sample of cells from inside the vagina. The swab goes to a lab, where it is tested for high-risk HPV types. There is no speculum and no need for a clinician to collect from the cervix directly.

A few important points about the US rollout:

• The 2026 ACOG option is clinician-ordered. This is not an over-the-counter product you buy off a shelf. A clinician orders an FDA-approved kit, and self-collection is often done in a private space at a clinic or pharmacy, with mailed-to-home models expanding over time.
• The test is for high-risk HPV only. A self-collected swab is suitable for HPV testing, not for a traditional Pap smear, because cytology still needs cells taken directly from the cervix.
• A positive self-collected HPV result is not the end of the process. It typically means you return for a clinician-collected sample, often cytology, to work out the next step. Self-collection is a front door to screening, not a replacement for follow-up.

The big appeal is access. Self-collection can reach people who avoid or cannot easily get a speculum exam, whether because of past trauma, discomfort, disability, cultural barriers, or simply distance from a clinic.

Who self-collection is and is not for

Self-collection under the 2026 guidance is for average-risk people aged 30 to 65 who are due for routine screening and have no current symptoms.

It is not the right path if any of the following apply:

• You have symptoms such as unusual bleeding, bleeding after sex, bleeding between periods, or unexplained pelvic pain. Symptoms need a clinical evaluation, not a screening swab.
• You are following up an abnormal result or a previous positive HPV test. Surveillance after an abnormal finding is a different process and usually needs clinician-collected samples.
• You are at higher than average risk, for example due to a weakened immune system, prior cervical precancer, or in-utero DES exposure. Higher-risk screening schedules are individualized.
• You are under 30 or under 21. The self-collection option applies to ages 30 to 65, and people aged 21 to 29 are screened with cytology.

In short, self-collection is a screening tool for people who feel well and are simply due for their check. It is not a way to investigate a symptom or shortcut follow-up of an abnormal result.

This is also where ACOG's "qualified" wording comes in. ACOG advises offering self-collection only if a patient prefers it and if the clinic has the infrastructure to handle results responsibly: a reliable way to notify people of results, document them, and refer for follow-up testing or treatment when needed. Expanding access without that scaffolding could, paradoxically, delay diagnosis for the people it is meant to help.

What to do

If you think self-collection might suit you, here is how to approach it.

1. Check whether you are due. Pull up the date of your last screening. If you are 30 to 65 and it has been three years or more since your last HPV-based test, you are likely due. If you are unsure, that is a good first question for your clinician.
2. Ask the direct question. Try: "I am due for cervical screening. Do you offer self-collected HPV testing, and am I a candidate for it?" Naming the test specifically helps.
3. Confirm the logistics. Ask whether the kit is FDA-approved, whether you collect on-site or at home, and how and when you will get your results.
4. Ask about follow-up before you test. A useful question: "If my HPV result is positive, what is the next step and who contacts me?" You want a clear plan, not a result that goes nowhere.
5. Do the swab as instructed. Follow the kit directions closely, since sample quality matters for an accurate result.
6. Record the date and your next due date. Set a reminder so the next screening does not slip. For self-collected HPV testing, the recommended interval is every three years.

If your clinic does not yet offer self-collection, ask when they expect to, and in the meantime do not skip screening. A clinician-collected test now is far better than waiting indefinitely for a self-collected option.

Red flags: when you still need a clinician visit

Screening is for people without symptoms. See a clinician promptly, rather than relying on a self-collected screening test, if you have any of the following:

• Bleeding after sex, between periods, or after menopause
• Unusual or persistent vaginal discharge with no clear cause
• Pelvic pain or pain during sex that is new or worsening
• A previous abnormal Pap or positive HPV result that needs follow-up

These can have many explanations, most of them not cancer, but they call for evaluation rather than routine screening. If you want help thinking through whether something counts as a symptom, our guide to vaginal health in 2026 is a useful starting point, and you can browse plain-language answers in our questions library.

How Femora helps

Screening only works if it actually happens on schedule, and that is where a tracking app earns its place.

Femora can hold your screening dates and send reminders so a three-year or five-year interval does not quietly stretch to seven or eight. Logging the date of your last test in one place also means you walk into an appointment knowing exactly when you are due, which makes the conversation about self-collection much easier to start.

If you are unsure whether you qualify for self-collection, what your result means, or whether a symptom needs a visit rather than a swab, you can chat with a health expert inside the app for guidance you can take to your clinician. It does not replace your doctor, but it helps you ask sharper questions and understand the answers.

You can download Femora to set up screening reminders and keep your cycle and symptom history in one private place.

The bigger picture

Self-collection is part of a wider shift toward HPV testing as the foundation of cervical screening, and toward meeting people where they are.

The same logic is already in motion in the UK. From early 2026, NHS England began offering at-home HPV self-sampling kits to people who are overdue for screening, building on the YouScreen trial, which suggested a similar program could bring hundreds of thousands of additional people into screening each year and reached a high share of participants from deprived and ethnic minority backgrounds.

The throughline on both sides of the Atlantic is the same. Cervical cancer is highly preventable when high-risk HPV is found early, and the biggest remaining problem is not the science of the test but the number of people who never get screened at all. Self-collection is a serious attempt to close that gap, paired with the warning that access only saves lives when follow-up is built in.

If you have been putting off your screening because of the exam, 2026 is a good year to ask what your options are now.

Ready to stay on top of your screening schedule? Download Femora.

Sources